Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect

Northera Suffers Generic Erosion In First Quarter

13 May 2021

• By John Davis

Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.

woman with migraine — Migraines can be debilitating • Source: Alamy

H. Lundbeck A/S’s new migraine preventive therapy, Vyepti (eptinezumab-jjmr), picked up sales momentum in the US in the first quarter of 2021, recovering the lost trajectory from launching at the start of the COVID-19 pandemic in 2020. And a second neurological product, the antidepressant, Brintellix/Trintellix (vortioxetine), is showing promise in patients with comorbidities of major depressive and generalized anxiety disorders, the company has reported.

According to Lundbeck’s president and CEO Deborah Dunsire, the US market is still experiencing some disruption in patient-physician interactions, but Vyepti sales grew by 50%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

15 May 2025

• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

15 May 2025

• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.